共 102 条
[1]
Siegel R(2012)Cancer statistics, 2012 CA Cancer J Clin. 62 10-12
[2]
Naishadham D(2009)Ovarian cancer Lancet. 374 1371-1382
[3]
Jemal A(2002)Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol. 20 1248-1259
[4]
Hennessy BT(1996)Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med. 334 1-6
[5]
Coleman RL(2009)Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm Gynecol Oncol. 114 26-31
[6]
Markman M(1988)Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors Am J Obstet Gynecol. 159 1094-1098
[7]
Bristow RE(2003)Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol. 21 3194-3200
[8]
Tomacruz RS(2009)Ovarian cancer Lancet. 374 1371-1382
[9]
Armstrong DK(2004)Critical evaluation of secondary cytoreduction in recurrent ovarian cancer Gynecol Oncol. 95 273-8
[10]
Trimble EL(2005)The role of secondary cytoreductive surgery for recurrent ovarian cancer Gynecol Oncol. 97 74-24